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OBJECTIVES: Chronic obstructive pulmonary disease(COPD) is a highly prevalent dis-
ease and the sixth cause of death in Korea. This study examined the national epide-
miology and economic impact of COPD in Korea. METHODS: This study used the
societal cost of illness framework, consisting of epidemiology of COPD, directmedical
costs,directnon-medical costs, and indirect costs.National-levelhealthsurvey results
and insurance claim databases were used to analyze annual healthcare utilization,
hospitalization costs and outpatient costs of the total Korean population (48 million
people). Using a data mining technique, we identified medical claims with interna-
tional classification of disease 10 codes for COPD and estimated the costs by amacro-
costingmethod.RESULTS: The prevalence rate of COPDbased on theGlobal Initiative
for chronic obstructive lung disease(GOLD) criteria was estimated at 13.1% and its
mortality rate was 14.9 persons per 1,000 population in 2008. According to the classi-
fication of the GOLD, for the population over 45 years, the stage 1 group accounted for
the largest proportion(55.2%), followed by the stage 2(37.2%), stage 3(6.4%), and stage
4(1.2%). The total societal cost of COPD in 2009 was estimated at $266.4 million for
700,812 patients. The directmedical cost for COPDwas $148.7million, which includes
hospitalization cost of $72.8 million and outpatient cost of $75.9 million. The direct
non-medical cost, involving transportation cost and caregiver cost, was estimated at
$20.4 million. Indirect costs associated with morbidity and mortality of COPD were
$97.3 million. CONCLUSIONS: The study showed that the COPD had a great effect on
healthcare costs, particularly thedirectmedical cost. Therefore, appropriate interven-
tion that result inpatientswithCOPDspending less time in thehospital are likely to be
cost effective and long-term regular management is also necessary to lower the eco-
nomic burden of COPD in Korea.
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OBJECTIVES: To develop a model which calculates economic consequences of
treatment of cattle at high risk of developing Bovine Respiratory Disease (BRD
high-risk cattle), themost common and economically detrimental cattle disease in
US feedlots. Themodel had to be easily adaptable to clinical variations and regional
and timely changes in cost data. METHODS: A decision tree was developed in MS
Excel evaluating the consequences of initial treatment of BRD high-risk cattle with
tulathromycin, florfenicol, and tilmicosin on total costs and losses associated with
BRD and its treatments over an entire feeding period. Clinical data were derived
from 5 comparative trials considering success rate of initial treatment of BRD high-
risk cattle, occurrence and outcome of subsequent BRD outbreaks, chronic cases,
andmortalities. Themodel allows the estimation of results separately according to
outcomes of one of the 5 clinical trials. Cost parameters included cattle purchase,
treatment costs (first and re-treatments), costs of chronic and dead cows (perspec-
tive of the producer). RESULTS: Considering cost data derived from multiple
sources as of 2010, total costs over the entire feeding period associated with first
and subsequent BRD treatments were lowest with tulathromycin, regardless of the
study selected as basis for efficacy data. Total treatment costs for one cattle ranged
from $27.78 to $54.38 (tulathromycin), $52.83 to $84.06 (florfenicol), and $41.35 to
$141.13 (tilmicosin), and cost savings with tulathromycin were calculated between
$19.65 and $43.59 (vs. florfenicol) and $9.77 and $86.75 (vs. tilmicosin), depending
on the clinical trial considered as basis for efficacy data. Savings with tulathromy-
cin were attributed to fewer BRD treatments, less chronics and mortalities.
CONCLUSIONS: Themodel allows the estimation of total costs of treatment of BRD
high-risk cattle considering various clinical outcomes as reported in 5 trials, being
easily adaptable to high variability of cost and income data in livestock.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a rising concern in
high population areas, such as Mexico City, where the prevalence is estimated at
around 8%. The objective of this study was to examine if the recently available
treatment for COPD, indacaterol, was more cost-effective than the therapeutic
alternatives already available. METHODS: A cost-effectiveness analysis was per-
formed from an institutional perspective (Mexican Institute of Social Security,
IMSS). The comparators used were salmeterol and tiotropium, both alternatives
available within the National Formulary and recommended by the National Treat-
ment Guidelines for COPD. Effectiveness data was taken from published literature;
the effectiveness parameter usedwas Forced Expiratory Volume in 1 second (FEV1);
dosage regimens compared were indacaterol 300 g vs. tiotropium 18 g, and in-
dacaterol 150 g vs. salmeterol 50 g. Resource use data was obtained from the
institution; total direct costs of physician consults, lab and image tests, hospital-
ization and emergency room visits, and treatments were considered. The source of
the unit costs was the institution, current for 2010. All costs are expressed in local
currency (Mexican Pesos, MXP). The time horizon was less than 1 year; no discount
rate was used. The analytical tool used to build the model was a decision tree. A
probabilistic sensitivity analysis was performed through a Monte Carlo simulation
with 100,000 iterations to confirm the robustness of the model. RESULTS: The
results show a cost-effectiveness ratio of $13 MXP per mL of FEV1 increased for
indacaterol, compared to $13.7 MXP for tiotropium. Likewise, a cost-effectiveness
ratio of $12.9 MXP permL of FEV1 increased for indacaterol, compared to $14.3 MXP
for salmeterol, confirmed that indacaterol is a more cost-effective alternative
(dominant) for the treatment of COPD. CONCLUSIONS: From an institutional per-
spective inMexico, indacaterol is amore cost-effective (dominant) alternative than
either tiotropium or salmeterol for the treatment of COPD.
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OBJECTIVES: To evaluate the cost-effectiveness of fluticasone furoate vs. mome-
tasone furoate in the treatment of ocular symptoms in allergic rhinitis patients in
Mexico.METHODS: A decision-analytic model was developed to estimate the cost-
effectiveness of fluticasone furoate vs. mometasone furoate. Patients initiated on
treatment either completed initial therapy or switched to second line therapy due
to non-response. Probability of a switch and resource use was based on expert
panel and literature. Costs were based on local drug acquisition costs, local cost
estimates for outpatient and hospitalization. Effectiveness was defined as the net
improvement in Total Ocular Symptom Score (TOSS) at 12 weeks from Keith PK.
2009 study. The analysis was carried out from the perspective of the Mexican
health care system and all costs are reported in 2010 US dollars. RESULTS: The
corresponding health effects were 0.47 net improvement TOSS for fluticaone fu-
roate and 0.31 for mometasone furoate regimen. The mean total cost of the fluti-
caone furoate regimenwas $ 627 compared with $ 827 for the furoatemometasone
regimen. Treatment with fluticasone furoate compared to treatment with mome-
tasone furoate was less costly and resulted in a greater net improvement of TOSS.
Probabilistic sensitivity analyses demonstrated that the cost savings observed
were maintained over a wide range of alternative values for costs and resource
utilization. CONCLUSIONS: Cost-effectiveness analysis indicated the dominance
of fluticasone furoate over mometasone furoate because of both lower costs and
greater efficacy. Cost savings with fluticasone furoate were attributable to lower
drug acquisition costs. In addition, a net improvement in ocular symptomsmay be
expected in allergic rhinitis patients.
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OBJECTIVES: In Central American countries, the economic burden of tobacco has
not been assessed. In Costa Rica, a study demonstrated that tobacco-related dis-
eases represent high costs for the health system. The aim of this study was to
assess the cost-effectiveness of varenicline compared to other existing strategies
for smoking cessation within a 20-year time horizon in an adult population cohort
from Central American and the Caribbean countries using the healthcare payer’s
perspective.METHODS: The Benefits of Smoking Cessation on Outcomes (BENESCO)
simulationmodelwas used for an adult cohort in Costa Rica, Panama, Nicaragua, El
Salvador and Dominican Republic (n  19,429,581). Smoking cessation therapies
compared were varenicline (0.5–2 mg/day) versus bupropion (300 mg/day); NRT
(5-10 mg/day) and unaided cessation. Effectiveness measures were: Life-Year
gained (LYG) and quality-adjusted life-year gained (QALY’s). Resource use and
costs data were obtained from country’s Ministry of Health and/or Social Security
Institutions (2008-2009). The model used a 3% discount rate for costs (expressed in
2009 US dollars) and health outcomes. Probabilistic sensitivity analyses (PSA) were
conducted and acceptability curves were constructed. RESULTS: Varenicline re-
duced smoking-related morbidity, mortality and healthcare costs. Mortality in the
varenicline arm was reduced by 5,738, 7,425 and 14,007 deaths compared with
bupropion, NRT and unaided cessation. The net average cost per additional quitter
showed that varenicline was cost-saving against competing alternatives. The cost
per additional quitter on varenicline was US$-269 compared with bupropion and
US$2,624 compared with unaided cessation. Cost-effectiveness analyses showed
that varenicline was the dominant strategy. At a willingness-to-pay of US$10,000/
QALY, the probability that varenicline is cost-effective met 100%. PSA results sup-
port the robustness of the findings.CONCLUSIONS: Smoking cessation therapywith
varenicline is cost-saving for Central American countries. These results could help to
reduce the tobacco related disease burden and align cost-containment policies.
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1Billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends,we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($80-95B worldwide sales). METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
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